Sio Capital Management LLC Position In United Therapeutics Corp (UTHR) Was Has Boosted

United Therapeutics Corporation (NASDAQ:UTHR) LogoInvestors sentiment decreased to 0.72 in Q2 2019. Its down 0.41, from 1.13 in 2019Q1. It dropped, as 69 investors sold UTHR shares while 94 reduced holdings. 50 funds opened positions while 68 raised stakes. 38.81 million shares or 4.33% less from 40.56 million shares in 2019Q1 were reported. Ubs Asset Mngmt Americas reported 57,987 shares. Vanguard Gp Incorporated stated it has 3.99 million shares. Us Comml Bank De holds 0% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 1,480 shares. Kbc Grp Nv invested 0.01% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Hrt Financial Ltd Co reported 21,567 shares. Franklin Incorporated holds 0% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 29,566 shares. Mufg Americas Hldg holds 331 shares. Sei Invests Co invested in 0% or 3,238 shares. Moreover, Citadel Advsrs Limited Liability Company has 0.02% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 687,901 shares. Connor Clark And Lunn Invest stated it has 69,075 shares or 0.03% of all its holdings. Fuller And Thaler Asset Mngmt invested in 128 shares. Shelton Capital Management invested in 2,770 shares or 0.01% of the stock. Manufacturers Life Insurance Co The holds 71,463 shares. Permanens Cap Lp reported 6,150 shares. Oak Ltd Oh reported 0.05% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR).

Sio Capital Management Llc increased its stake in United Therapeutics Corp (UTHR) by 146.3% based on its latest 2019Q2 regulatory filing with the SEC. Sio Capital Management Llc bought 49,237 shares as the company’s stock declined 20.20% . The institutional investor held 82,892 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $6.47M, up from 33,655 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in United Therapeutics Corp for a number of months, seems to be bullish on the $3.40 billion market cap company. The stock increased 1.00% or $0.8 during the last trading session, reaching $80.62. About 230,249 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 34.11% since September 13, 2018 and is downtrending. It has underperformed by 34.11% the S&P500.

Sio Capital Management Llc, which manages about $116.75 million and $414.77M US Long portfolio, decreased its stake in Globus Medical Inc (NYSE:GMED) by 100,000 shares to 102,827 shares, valued at $4.35M in 2019Q2, according to the filing. It also reduced its holding in Cvs Health Corp (NYSE:CVS) by 253,333 shares in the quarter, leaving it with 113,738 shares, and cut its stake in Emergent Biosolutions Inc (NYSE:EBS).

More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: Nasdaq.com which released: “RSI Alert: United Therapeutics (UTHR) Now Oversold – Nasdaq” on May 31, 2019, also Nasdaq.com with their article: “United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y – Nasdaq” published on August 01, 2019, Finance.Yahoo.com published: “Before You Buy United Therapeutics Corporation (NASDAQ:UTHR), Consider Its Volatility – Yahoo Finance” on May 08, 2019. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Bizjournals.com and their article: “Mayo Clinic unveils state of the art lung facility, incubator – Jacksonville Business Journal” published on August 22, 2019 as well as Nasdaq.com‘s news article titled: “United Therapeutics’ Trevyent NDA for PAH Accepted by FDA – Nasdaq” with publication date: September 12, 2019.

United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage

Among 5 analysts covering United Therapeutics (NASDAQ:UTHR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. United Therapeutics has $27300 highest and $9000 lowest target. $136.83’s average target is 69.72% above currents $80.62 stock price. United Therapeutics had 12 analyst reports since March 23, 2019 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $160 target in Tuesday, March 26 report. Jefferies upgraded the shares of UTHR in report on Thursday, August 1 to “Hold” rating. The company was upgraded on Friday, May 17 by UBS. The firm has “Outperform” rating given on Thursday, May 2 by Wedbush. The company was maintained on Tuesday, March 26 by Credit Suisse. The stock has “Buy” rating by Ladenburg Thalmann on Thursday, August 1.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.